On August 29, 2025, the U.S. Department of Justice (DOJ) announced the creation of a new Trade Fraud Task Force (“Task Force”).
DOJ touts this cross-agency initiative as being designed “to aggressively pursue enforcement actions against any parties who seek to evade tariffs and other duties”—promising “robust enforcement against importers and other parties who seek to defraud the United States.”
Created to further the administration’s “America First Trade Policy” announced on January 20, 2025, the Task Force will consist of civil and criminal components of the DOJ along with U.S. Customs and Border Protection and Homeland Security Investigations. It will focus on ensuring compliance with trade laws, including payment of all tariffs and duties (e.g., antidumping and countervailing duties, Section 301 tariffs, and other customs obligations). DOJ promises increased parallel civil and criminal actions under the False Claims Act (FCA), Tariff Act, and federal criminal statutes related to trade fraud and conspiracy.
On February 1, 2022, the U.S. Department of Justice (DOJ) released its annual False Claims Act (FCA) enforcement statistics for fiscal year (FY) 2021.[1]
With collections amounting to $5.6 billion, FY 2021 marks DOJ’s largest annual total FCA recovery since FY 2014, and more than twice the $2.3 billion received in FY 2020. FY 2021 was also a record-shattering year for DOJ as it relates to health care fraud enforcement; over $5 billion (90% of the total) was obtained from cases pursued against individuals and entities in the health care and life sciences industries.
Blog Editors
Recent Updates
- HHS OIG Issues Favorable Advisory Opinion Regarding Surgical Supply Discounts to Ambulatory Surgery Centers in Exchange for Software Purchases
- Health Care Workplace Violence Legislation Heats Up in 2026
- DOGE's Attempt to Crowdsource Medicaid Fraud Scrutiny: Is This the Future of Healthcare Fraud Investigations?
- Feds vs. the States: Dr. Mehmet Oz Announces an Investigation Into New York’s Medicaid Program
- U.S. Supreme Court to Weigh Induced Infringement Case Regarding ‘Generic Version of Vascepa®’